Spero Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-38.7M | $-25.5M | $-10.2M |
| Depreciation & Amortization | $363.0K | $279.0K | $11.0K |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $1.4M | $180.0K | $21.0K |
| Net Cash from Operating Activities | $-39.1M | $-29.0M | $-9.6M |
| Investing Activities | |||
| Capital Expenditures | $27.0K | $830.0K | $232.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-27.0K | $-830.0K | — |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $116.1M | $34.4M | — |
| Net Change in Cash | $77.0M | $4.6M | $5.4M |
| Free Cash Flow | $-39.1M | $-29.8M | $-9.8M |